{"id":"anti-egfr-containing-regimen","safety":{"commonSideEffects":[{"rate":"null","effect":"Rash"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition prevents the proliferation of cancer cells that overexpress EGFR.","oneSentence":"Inhibits the epidermal growth factor receptor (EGFR)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:02.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT04495621","phase":"PHASE1, PHASE2","title":"MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2020-07-20","conditions":"Metastatic Colorectal Cancer","enrollment":29},{"nctId":"NCT01750918","phase":"PHASE1, PHASE2","title":"BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-19","conditions":"Cancer","enrollment":166},{"nctId":"NCT04890704","phase":"EARLY_PHASE1","title":"Curcuminoids and Contrast-induced Acute Kidney Injury","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2018-10-01","conditions":"Acute Kidney Injury, Contrast Media Toxicity, Curcuminoid","enrollment":96},{"nctId":"NCT02508077","phase":"PHASE2","title":"FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2016-02-16","conditions":"Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer","enrollment":1},{"nctId":"NCT00503685","phase":"PHASE2","title":"Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-06","conditions":"Colorectal Cancer","enrollment":65},{"nctId":"NCT02831842","phase":"","title":"A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-09","conditions":"Colorectal Cancer","enrollment":4278},{"nctId":"NCT00510627","phase":"PHASE4","title":"Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases","status":"WITHDRAWN","sponsor":"Boston Scientific Corporation","startDate":"2007-08","conditions":"Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-EGFR-Containing Regimen","genericName":"Anti-EGFR-Containing Regimen","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits the epidermal growth factor receptor (EGFR) Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}